The Use of Intravenous Lidocaine in Perioperative Medicine: Anaesthetic, Analgesic and Immune-Modulatory Aspects.
Ingrid Wing-Sum Lee, Stefan Schraag
https://pubmed.ncbi.nlm.nih.gov/35743617Actively Recruiting
Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID07089173
Effect-site Concentration of Remifentanil to Suppress Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Trial
Led by Peking University Shenzhen Hospital · Updated on 2025-09-22
99
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effect-site target concentration of remifentanil needed to suppress cardiovascular responses during tracheal intubation in patients undergoing general anesthesia. This randomized controlled trial includes patients classified as ASA physical status I-II, who are scheduled for elective surgery requiring endotracheal intubation. The study aims to compare remifentanil concentrations when combined with etomidate and either lidocaine or sufentanil, or a placebo, to understand how these combinations affect cardiovascular responses during anesthesia induction. Participants will be randomly assigned to one of three groups: a placebo group receiving normal saline with etomidate, a lidocaine group receiving lidocaine with etomidate, or a sufentanil group receiving sufentanil with etomidate. Each group will also receive a target-controlled infusion of remifentanil. The primary outcome is the median effective concentration of remifentanil (EC50) required to suppress the intubation response. Secondary outcomes include the 90% effective concentration (EC90) of remifentanil and measurements of mean arterial pressure, heart rate, and bispectral index before and after intubation. Participants will be monitored throughout the operative day and on postoperative days 1 and 5 for complications. Researchers will assess cardiovascular and anesthesia-related responses during and after intubation using clinical measurements. The study is expected to enroll a total of 99 patients across all groups. The participation period includes anesthesia induction, intubation, and short-term postoperative monitoring, with data collection continuing through study completion, approximately one year after enrollment begins.
CONDITIONS
Brief Title
The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study
Who Can Participate
Age: 18Years - 65Years
All Genders
Eligibility Criteria
You may qualify if you...
- Patients scheduled for elective surgery under general anesthesia with endotracheal intubation
- Classified as ASA physical status I-II
- Aged between 18 and 65 years
You will not qualify if you...
- Age younger than 18 or older than 65 years
- Body mass index (BMI) over 30 kg/m² or under 18.5 kg/m²
- Diagnosis of hypertension or severe cardiovascular diseases such as myocardial infarction, heart failure, atrial fibrillation, atrioventricular block, or moderate-to-severe valvular diseases
- Diagnosis of respiratory diseases including acute exacerbation of chronic obstructive pulmonary disease, acute respiratory distress syndrome, acute asthma attack, moderate-to-severe pulmonary hypertension, or severe pneumonia
- Diagnosis of obstructive sleep apnea syndrome or history of difficult intubation or anticipated difficult airway
- Renal, hepatic, or hematologic diseases
- High risk of aspiration or reflux
- Current use of analgesics for chronic pain or beta-blockers for cardiovascular diseases
- Current use of psychotropic medications
- Contraindications to remifentanil or sufentanil such as known hypersensitivity, use of monoamine oxidase inhibitors, myasthenia gravis, or conditions causing respiratory depression
- Contraindications to lidocaine including allergy to local anesthetics, Adams-Stokes syndrome, Wolff-Parkinson-White syndrome, or severe cardiac conduction block
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Single anesthesia induction session
Participants receive anesthesia induction with either placebo (normal saline), lidocaine, or sufentanil combined with etomidate, along with a target-controlled infusion of remifentanil to suppress intubation responses.
1 visit (in-person)
Follow-up
Duration - 6 days
Participants are monitored for complications on the operative day and postoperative days 1 and 5.
3 visits (in-person)
Trial Site Locations
Total: 1 location
1
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Actively Recruiting
Loading map...
Research Team
Z
zhencong jiang
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
The effect of remifentanil on the bispectral index change and hemodynamic responses after orotracheal intubation.
B Guignard, C Menigaux, X Dupont...
https://pubmed.ncbi.nlm.nih.gov/10624998Intravenous boluses of fentanyl, 1 μg kg⁻¹, and remifentanil, 0.5 μg kg⁻¹, give similar maximum ventilatory depression in awake volunteers.
J Gelberg, C Jonmarker, O Stenqvist...
https://pubmed.ncbi.nlm.nih.gov/22440314Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity.
Brian A Baldo
https://pubmed.ncbi.nlm.nih.gov/33974096Objective Characterization of Opiate-Induced Chest Wall Rigidity.
Charles Trujillo, David Rudd, Hakan Ogutcu...
https://pubmed.ncbi.nlm.nih.gov/32566433Understanding Research Methods: Up-and-down Designs for Dose-finding.
Assaf P Oron, Michael J Souter, Nancy Flournoy
https://pubmed.ncbi.nlm.nih.gov/35819863Remifentanil for the insertion and removal of long-term central venous access during monitored anesthesia care.
Crina L Burlacu, Kevin McKeating, Alan J McShane
https://pubmed.ncbi.nlm.nih.gov/21663812Effect of an opioid-free anesthetic on postoperative opioid consumption after laparoscopic bariatric surgery: a prospective, single-blinded, randomized controlled trial.
Josiah Joco Perez, Joseph D Strunk, Octavio M Preciado...
https://pubmed.ncbi.nlm.nih.gov/38839427The effect-site concentration of remifentanil blunting cardiovascular responses to tracheal intubation and skin incision during bispectral index-guided propofol anesthesia.
Andrea Albertin, Andrea Casati, Lombardo Federica...
https://pubmed.ncbi.nlm.nih.gov/15976218Comparison of intravenous magnesium sulphate and lidocaine for attenuation of cardiovascular response to laryngoscopy and endotracheal intubation in elective surgical patients at Zewditu Memorial Hospital Addis Ababa, Ethiopia.
Abebaw Misganaw, Mulualem Sitote, Suliman Jemal...
https://pubmed.ncbi.nlm.nih.gov/34061894